Beyond the signaling effect role of amyloid-ss42 on the processing of APP, and its clinical implications

Exp Neurol 225:51-4 (2010)
  Copy   BIBTEX


Alzheimer's disease currently has over 6 million victims in the USA, alone. The recently FDA approved drugs for AD only provide mild, transient relief for symptoms without addressing underlying mechanisms to a significant extent. Basic understanding of the activities of the amyloid beta peptide and associated proteins such as beta-site APP-cleaving enzyme 1 is necessary to develop effective medical responses to AD. Recently , Tabaton et al. have presented a model of both non-pathological and pathological Abeta activities and suggest potential therapeutic pathways based on their proposed framework of Abeta acting as the signal that induces a kinase cascade, ultimately stimulating transcription factors that upregulate genes such as BACE1. We respond by presenting evidence of Abeta's other activities, including protection against metal-induced reactive oxidizing species , modification of cholesterol transport, and potential activity as a transcription factor in its own right. We touch upon clinical implications of each of these functions and highlight the currently unexplored implications of our suggested novel function of Abeta as a transcription factor. Abeta appears to be a highly multi-functional peptide, and any or all of the pathways it engages in is a likely candidate for antiAD drug development



    Upload a copy of this work     Papers currently archived: 94,385

External links

Setup an account with your affiliations in order to access resources via your University's proxy server

Through your library

Similar books and articles


Added to PP

9 (#1,284,873)

6 months
3 (#1,240,593)

Historical graph of downloads
How can I increase my downloads?

Author's Profile

Bryan Maloney
Indiana University Purdue University, Indianapolis

References found in this work

No references found.

Add more references